This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fernholm, R. Articles by Thorén, M. Search for Related Content PubMed PubMed Citation Articles by Fernholm, R. Articles by Thorén, M.

Growth Hormone Replacement Therapy Improves Body Composition and Increases Bone Metabolism in Elderly Patients with Pituitary Disease¹

Department of Endocrinology and Diabetology, Karolinska Hospital (R.F., A.H., M.T.), SE-171 76 Stockholm, Sweden; Department of Endocrinology, University Hospital MAS (M.B.), SE-205 02 Malmo, Sweden; Department of Internal Medicine, Norrlands University Hospital (E.H.), SE-901 85 Umea, Sweden; Department of Mineral Metabolism, Jerry L. Pettis Veterans Administration Medical Center (D.J.B., S.M.), Loma Linda, California 92357

Address all correspondence and requests for reprints to: Dr. Marja Thorén, Department of Endocrinology and Diabetology, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail: marja{at}divmed.ks.se

Although a specific GH deficiency (GHD) syndrome in the adult and the response to GH replacement therapy are well recognized, there are few data available on the effect of GH replacement therapy in elderly GH-deficient patients. We studied the effect of GH therapy on body composition and bone mineral density measured by dual energy x-ray absorptiometry, markers for bone metabolism, insulin-like growth factors (IGFs), and IGF-binding proteins (IGFBPs) in 31 patients (6 women and 25 men; aged 60–79 yr; mean, 68 yr) with multiple pituitary hormone deficiencies. The GH response to arginine or insulin was below 3 µg/L (9 mU/L) in all subjects. They were randomized to GH (Humatrope, Eli Lilly & Co.) or placebo for 6 months, followed by 12 months of open treatment. The dose was 0.05 IU/kg·week for 1 month, and after that it was 0.1 IU/kg·week divided into daily sc injections (0.75–1.25 IU/day).

There were no changes in any of the measured variables during placebo treatment. GH treatment normalized serum IGF-I in a majority of the patients and increased IGFBP-3 and -5 as well as IGFBP-4 and IGF-II to values within normal range. Lean body mass was increased, and the increase at 6 and 12 months correlated with the increase in IGF-I (r = 0.46; P = 0.010 and r = 0.54, respectively; P = 0.003). GH treatment caused a modest, but highly significant, reduction of total body fat. Mean bone mineral density was not different from that in healthy subjects of the same age and did not change during the observation period. Markers for bone formation (bone-specific alkaline phosphatase activity, osteocalcin, and procollagen I carboxyl-terminal peptide in serum) increased within the normal range, and levels were sustained throughout the study. The bone resorption marker (pyridinoline in urine) was significantly elevated for 12 months. Side-effects were mild, mostly attributed to fluid retention. In two patients with normal glucose tolerance at the start of the study, pathological glucose tolerance occurred in one patient and was impaired in one.

In conclusion, elderly patients with GHD respond to replacement therapy in a similar manner as younger subjects, with an improvement in body composition and an increase in markers for bone metabolism. Side-effects are few, and elderly GHD patients can be offered treatment. As long-term risks are unknown, GH doses should be titrated to keep IGF-I within the age-related physiological range.

This article has been cited by other articles:

				M. Sathiavageeswaran, P. Burman, D. Lawrence, A. G Harris, M. G Falleti, P. Maruff, and J. Wass Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study Eur. J. Endocrinol., April 1, 2007; 156(4): 439 - 447. [Abstract] [Full Text] [PDF]

				G Gotherstrom, B-A Bengtsson, I Bosaeus, G Johannsson, and J Svensson Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 55 - 64. [Abstract] [Full Text] [PDF]

				C. Franco, G. Johannsson, B.-A. Bengtsson, and J. Svensson Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4408 - 4414. [Abstract] [Full Text] [PDF]

				K. E. Govoni, S. K. Lee, R. B. Chadwick, H. Yu, Y. Kasukawa, D. J. Baylink, and S. Mohan Whole genome microarray analysis of growth hormone-induced gene expression in bone: T-box3, a novel transcription factor, regulates osteoblast proliferation Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E128 - E136. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				R. D. Murray, J. E. Adams, and S. M. Shalet A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 432 - 438. [Abstract] [Full Text] [PDF]

				H. D. White, A. M. Ahmad, B. H. Durham, A. Patwala, P. Whittingham, W. D. Fraser, and J. P. Vora Growth Hormone Replacement Is Important for the Restoration of Parathyroid Hormone Sensitivity and Improvement in Bone Metabolism in Older Adult Growth Hormone-Deficient Patients J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3371 - 3380. [Abstract] [Full Text] [PDF]

				P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, and P. Chanson Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2192 - 2199. [Abstract] [Full Text] [PDF]

				R. D. Murray, B. Columb, J. E. Adams, and S. M. Shalet Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1124 - 1130. [Abstract] [Full Text] [PDF]

				T.-J. Wu, S.-M. Huang, R. L. Taylor, and P. C. Kao Thyroxine Effects on Serum Insulin-like Growth Factor I Levels, Anthropometric Measures, and Body Composition in Patients After Thyroidectomy Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 423 - 428. [Abstract] [Full Text] [PDF]

				A. F. Attanasio, P. C. Bates, K. K. Y. Ho, S. M. Webb, R. J. Ross, C. J. Strasburger, R. Bouillon, B. Crowe, K. Selander, D. Valle, et al. Human Growth Hormone Replacement in Adult Hypopituitary Patients: Long-Term Effects on Body Composition and Lipid Status--3-Year Results from the HypoCCS Database J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1600 - 1606. [Abstract] [Full Text] [PDF]

				R. A. French, S. R. Broussard, W. A. Meier, C. Minshall, S. Arkins, J. F. Zachary, R. Dantzer, and K. W. Kelley Age-Associated Loss of Bone Marrow Hematopoietic Cells Is Reversed by GH and Accompanies Thymic Reconstitution Endocrinology, February 1, 2002; 143(2): 690 - 699. [Abstract] [Full Text] [PDF]